These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 29023366)

  • 1. Personalized Nanomedicine: A Revolution at the Nanoscale.
    Fornaguera C; García-Celma MJ
    J Pers Med; 2017 Oct; 7(4):. PubMed ID: 29023366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoinformatics and Personalized Medicine: An Advanced Cumulative Approach for Cancer Management.
    Khan F; Akhtar S; Kamal MA
    Curr Med Chem; 2023; 30(3):271-285. PubMed ID: 35692148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicines accessible in the market for clinical interventions.
    Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
    J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances and challenges in nanocarriers and nanomedicines for veterinary application.
    Carvalho SG; Araujo VHS; Dos Santos AM; Duarte JL; Silvestre ALP; Fonseca-Santos B; Villanova JCO; Gremião MPD; Chorilli M
    Int J Pharm; 2020 Apr; 580():119214. PubMed ID: 32165220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine applied to translational oncology: A future perspective on cancer treatment.
    Bregoli L; Movia D; Gavigan-Imedio JD; Lysaght J; Reynolds J; Prina-Mello A
    Nanomedicine; 2016 Jan; 12(1):81-103. PubMed ID: 26370707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up.
    Operti MC; Bernhardt A; Grimm S; Engel A; Figdor CG; Tagit O
    Int J Pharm; 2021 Aug; 605():120807. PubMed ID: 34144133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine: Principles, Properties, and Regulatory Issues.
    Soares S; Sousa J; Pais A; Vitorino C
    Front Chem; 2018; 6():360. PubMed ID: 30177965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The nanomedicines alliance: an industry perspective on nanomedicines.
    Malinoski FJ
    Nanomedicine; 2014 Nov; 10(8):1819-20. PubMed ID: 25038497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.
    Farjadian F; Ghasemi A; Gohari O; Roointan A; Karimi M; Hamblin MR
    Nanomedicine (Lond); 2019 Jan; 14(1):93-126. PubMed ID: 30451076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging nanotherapeutics for antithrombotic treatment.
    Zhao Z; Yang F; Zhang X; Sun J; He Z; Luo C
    Biomaterials; 2020 Oct; 255():120200. PubMed ID: 32563945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
    Halwani AA
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping of the available standards against the regulatory needs for nanomedicines.
    Halamoda-Kenzaoui B; Holzwarth U; Roebben G; Bogni A; Bremer-Hoffmann S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1531. PubMed ID: 29923692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory aspects on nanomedicines.
    Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
    Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress and challenges in the translation of cancer nanomedicines.
    Tong F; Wang Y; Gao H
    Curr Opin Biotechnol; 2024 Feb; 85():103045. PubMed ID: 38096768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Artificial intelligence aids in development of nanomedicines for cancer management.
    Tan P; Chen X; Zhang H; Wei Q; Luo K
    Semin Cancer Biol; 2023 Feb; 89():61-75. PubMed ID: 36682438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nanomedicine: application of nanotechnology in medicine. Opportunities in neuropsychiatry].
    Szebeni J
    Neuropsychopharmacol Hung; 2011 Mar; 13(1):15-24. PubMed ID: 21451188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects.
    Zhang P; Xiao Y; Sun X; Lin X; Koo S; Yaremenko AV; Qin D; Kong N; Farokhzad OC; Tao W
    Med; 2023 Mar; 4(3):147-167. PubMed ID: 36549297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical-, chemical-, and biological-responsive nanomedicine for cancer therapy.
    Liao J; Jia Y; Wu Y; Shi K; Yang D; Li P; Qian Z
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jan; 12(1):e1581. PubMed ID: 31429208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.